1 Title Page

2 HbA1c and FIB-4 as Serologic Markers for the Risk of Progression of Stage A Heart

3 Failure

4 First author: Grigg DO

5 Authors:

6 William Grigg DO 1, Faisal Mahfooz MD 1, Dharmista Chaudhary MD 1, Isain

7 Zapata PhD 2, Douglas Duffee MD, MDiv, FACP 1, 3.

8 Affiliations:

9 1 Department of Internal Medicine, Parkview Medical Center, Pueblo, CO 81003

10 2 Department of Biomedical Sciences, Rocky Vista University, Parker, CO 80134

11 3 Department of Graduate Medical Education, Parkview Medical Center, Pueblo,

12 CO 81003

13 NO organizational funding support

14 Corresponding author:

15 Douglas Duffee MD, MDiv, FACP. Mail Address: 315 W. 15th St. Pueblo, Colorado

16 81003. Phone: +1(719)595-7968. Email: douglas_duffee@parkviewmc.com

17 Total word count = 3200

18 Total pages = 15

19 Subject terms: Diabetic Cardiomyopathy, HbA1c, Glyco%, Fib-4 index, Diastolic

20 dysfunction, Stage A heart failure

21

22

23

Abstract

Background-- The classic association of glycemic control as represented by glycosylated hemoglobin (Glyco% or HbA1c) with progression of micro and macro vascular clinical complications is well documented. However, use of the advanced glycation end product (AGE) axis as a marker for early diastolic hemodynamic changes leading to clinical heart failure has been suggested but is less well characterized. This study explored the association between elevated Glyco% and Fibrosis 4 (FIB-4, a 4-component marker for liver fibrosis) values and worsening measures of diastolic cardiac function in order to assess their utility as early serologic markers in cardiovascular disease prevention.

Methods and Results-- A Retrospective cohort analysis was conducted in 102 patients presenting to the Parkview Medical Center health system who had received a full resting echo characterized by normal systolic ejection fraction and clinical risk factors associated with stage A heart failure in conjunction with Glyco% and FIB-4 scores all within a 3-month time window. Using regression analysis, measures of diastolic cardiac function were assessed in conjunction with rising Glyco% levels characterized as <6.5 and > 6.5 and FIB-4 scores after controlling for the presence of hypertension, coronary artery disease and valvular heart disease. Glyco% levels > 6.5 were significantly associated with a higher E/e' ratio and closely associated with an elevated left atrial volume index both indicative of elevated left atrial pressure as a sensitive marker for diastolic cardiac dysfunction. FIB-4 scores did not appear to be clinically associated with progression of diastolic dysfunction.

Conclusions—Glyco%, long known to be a marker for metabolic glycemic control can also act as an early marker for identifying patients at increased risk for the progression of stage A heart failure. FIB-4 scores cannot.

Registration—

<https://clinicaltrials.gov/ct2/show/NCT04450576?term=duffee&draw=2&rank=3>

53 Text

54 Introduction-- The classic association of glycemic control, as represented by
 55 glyco%, with progression or improvement of microvascular and macrovascular
 56 clinical complications is well documented¹⁻⁵. Additionally, while the association of
 57 glyco% elevation with an advanced clinical cardiovascular syndrome described as
 58 diabetic cardiomyopathy (beyond the classic cardiac risk factors associated with
 59 diabetes mellitus) has also been well documented the use of advanced glycation
 60 end products (AGE) as both a marker of and treatment target for the early
 61 diastolic hemodynamic changes of diabetic cardiomyopathy has been suggested
 62 but less well characterized^{6-8,14}. In light of newer diabetic agents such as sglt2
 63 inhibitors, which exert a cardio protective natriuretic effect in addition to a
 64 hypoglycemic effect, markers for early initiation of these medications both inside
 65 and outside the diabetic context, are important to elucidate. Stage A heart failure
 66 is defined as persons with normal cardiac structure and function who have
 67 predisposing risks for cardiovascular disease but have not yet manifested
 68 symptoms of heart failure⁹⁻¹¹. Estimates suggest that Stage A heart failure may
 69 comprise greater than 50% of a community's patient population and are patients
 70 commonly seen in primary care, endocrinology, cardiology and other clinics⁵.

71 In light of cardio metabolic agents such as sglt2 inhibitors which show promise in
 72 cardiovascular disease primary prevention¹²⁻¹³, stage A heart failure patients may
 73 be an important target for a new therapeutic mechanism to deploy widely in
 74 preventative cardiovascular care. Showing an association between a commonly
 75 used metabolic marker and progressive hemodynamic cardiac disease would
 76 provide support for the logic of initiating medication therapy classically prescribed
 77 in the diabetic context to earlier use in the cardiac context with or without a
 78 concomitant indication for hypoglycemic therapy. Our study examined whether
 79 glyco% could be isolated as a hemodynamic marker of diastolic cardiac
 80 dysfunction in diabetics with stage A heart failure who may or may not yet need
 81 initiation or titration of hypoglycemic therapy. Secondly a non-invasive easily
 82 obtainable marker for liver fibrosis (FIB-4) was also assessed for its correlation to
 83 diastolic function and potential utility as a treatment marker.

Methods--

Participants--A community-based population cohort registry of all patients was identified by retrospective chart review who had presented to Parkview Medical Center's in-patient and outpatient services in Pueblo County Colorado from 1/2019 to 6/2020 and who had obtained a full resting echo characterized by normal LV systolic function in conjunction with glyco%, brain natriuretic peptide (BNP), CBC and CMP within a concomitant 3-month time frame. 2263 patients were identified. A sample of 102 participants was randomly selected for this study. The selected sample size was determined by power analysis ($1-\beta > 0.8$) for detection of a 5% change in Left atrial volume (LAV) examining the registry from most to less recent index encounter to a p value less than 0.05 until the N value was met. We also included a measure of liver fibrosis as estimated by the FIB-4 equation to assess for an association between a non-invasive marker for liver fibrosis and the same measures of diastolic cardiac function and a measure of the glycemic status of study groups at a cutoff level of 6.5 to include those with mild diabetes who may not yet require hypoglycemic therapy according to current guidelines.¹⁵ Patient's age, gender (M=Male, F=Female) Body Mass index (BMI), Body Surface Area (BSA), Brain Natriuretic Peptide (BNP), previous history of hypertension (HTN), cardiac valvular disease and Coronary Artery Disease (CAD) were also recorded. All data was compiled from retrospective medical records for the participants selected for the sample. This study was sanctioned and approved by the Parker Medical Center Institutional Review Board.

Echocardiography--Transthoracic echocardiography was performed in accordance with published standards and interpreted by a board-certified cardiologist independent of any knowledge of this study¹⁶. The presence of hypertension was defined as greater than 140/90 measured closest in time to the index echocardiogram. Valvular disease was defined as any regurgitation or stenosis noted to be greater than mild. Coronary artery disease was defined as any of the following: any regional wall motion abnormality on echo and/or cardiac catheterization showing at least one vessel with 50% or more stenosis. All labs were processed through Parkview's central laboratory.

Statistical analysis--Means, standard deviation and range were calculated for continuous variables while frequencies and proportional percentages were calculated for categorical variables. All descriptive statistics were calculated using PROC MEANS and PROC FREQ from SAS/STAT v.9.4 (SAS Institute, Cary NC). Generalized Additive Models (GAMs) were used to evaluate the association of the dependent variables Glycemic percentage (Glyco%) and liver Fibrosis (Fib-4) to the independent variables of HTN, Valvular disease, CAD, Age, BMI, BNP, LAVI and E/e'. Effects were introduced into a semiparametric model by including the effects of gender, HTN, valve disease and CAD as parametric independent variables (categorical variables) and age, BMI, BNP, LAVI and E/e' as smoothing splines with 3 degrees of freedom (continuous variables). Models were fitted independently by dependent variable (Glyco% and Fib-4) and assumed a Gaussian distribution for the residuals. Some variables were removed from the final model to avoid multi-collinearity: first, BMI and BSA which are intimately correlated¹⁷ and thus, BMI was the only one included; second, E, Lateral e' and E/e' are functionally related with each other and thus only E/e' was included in the model; last, LAVI and LADI where only LAVI was included in the model since it is the strongest method to predict any and moderate to severe diastolic dysfunction.¹⁸ All modeling was performed using PROC GAM in SAS/STAT v.9.4. Modeling effects are displayed as Risk Ratios with their 95% confidence intervals and non-linearity associations of the continuous variables evaluated as smoothing splines are evaluated through an analysis of deviance using a cubic pattern (3 degrees of freedom). Smoothing component plots included a 95% curve-wise Bayesian confidence band for each component.. Two-tailed P-values <0.05 were considered statistically significant

Results—In total, 102 patients were retrospectively identified who met inclusion and exclusion criteria. Their descriptive characteristics which include mean, standard deviation and range of values are shown in Table 1 for continuous variables and frequency and percentage proportion are shown in Table 2 for categorical variables. Patients with a left ventricular ejection fraction less than 50% were excluded.

Parameter estimates obtained through GAMs displayed as risk ratio significant association ($p < 0.05$) between Glyco% (HbA1c) with BMI ($P=0.0043$) and E/e' ($P=0.0345$). For both models, Glyco% and Fib-4, neither sex nor comorbidity confounders of CAD, Valve disease and HTN were significantly associated. No significant associations to Fib-4 in general were detected in this model mode. However, spline smoothing components for linearly defined effects are presented in Figure 2 where only one significant spline smoothing component was detected for BNP ($P=0.0019$, through analysis of deviance) in the Fib-4 model. Although its association remained as non-significant towards Fib-4 prediction ($P=0.2043$).

On a subsequent model iteration where parameter estimates were differentiated based on Glyco% grouping low group vs high group (the “low group” being defined as having Glyco% 6.5 or less while the “high group” being defined as having Glyco% over 6.5) detected only increased risk associated to age for the low group when estimating Glyco%. This data is presented in Table 3. Also in these models, neither sex nor comorbidity associations to Glyco% and Fib-4 were detected. In summary, some predictive potential for BMI and E/e' was observed for Glyco% models adjusted for comorbidities although no comorbidities were associated. For low group vs high group models only age was detected as significantly predictive. No predictive potential was detected in general for Fib-4 criteria in the main model and in the subsequent low group vs high group model iteration.

Discussion

AGE formation is characterized by the glycation of plasma proteins during longstanding hyperglycemia. These AGE's then stimulate transmembrane receptors of advance glycation end products (rAGE) on somatic cells including cardiac myocytes resulting in alteration of intracellular signaling, gene expression, release of pro-inflammatory molecules and free radicals.¹⁹ These processes at least in part are thought to play a role in the development of cardiac fibrosis independent of the classic vascular complications related to diabetes mellitus. In contrast to transmembrane rAGE, soluble receptors for advance glycation end products (sRAGE) function to reduce risk associated with transmembrane rAGE by

the pre-transmembrane binding of AGE's and subsequent reduction of intracellular rAGE signaling. Specific sRage's have been identified and may have the potential to serve as markers for AGE related cardiac risk.²⁰ As an early glycation end product, glyco% is nicely positioned as a hemodynamic risk marker inside this mechanism. Additionally, as lipids are thought to play a role in hepatic steatosis and liver fibrosis as well as in cross linking to form more advanced glycation end products capable of stimulating transmembrane rAGE, easily obtainable markers for liver fibrosis could serve as markers for cardiac fibrosis²¹ which is what prompted the evaluation of FIB-4 in this study.

Stage A heart failure patients, namely those with preclinical risk factors for progression to more advanced heart failure stages are an attractive cohort to study in that early intervention may provide significant attenuation of disease in this patient population. The definition of stage A heart failure in this study was applied to a cohort primarily defined by normal LV systolic function. In controlling for patients with underlying hypertension, CAD and valvular heart disease we further isolated the cohort to a stage A definition.²² The difficulty was in using diastolic dysfunction as an independent variable which could be seen as excluding our cohort from true stage A characteristics. In that the degree of diastolic dysfunction based on E/A changes needed to advance patients from the stage A category is not clear in the definition of stage A heart failure, we tried to utilize the more sensitive "pre-clinical" markers for left atrial pressure and chronic diastolic dysfunction LAVI and E/e'.

The use of the dependent variables glyco% and FIB-4 was designed to capture simple and easily obtainable markers for cardiac fibrosis. In that current diabetes guidelines recommend a goal for hypoglycemic therapy to a glyco% less than 7.5, defining the study group as those who meet a definition for DM but may not yet require hypoglycemic therapy makes the results more applicable for cardiac risk reduction as opposed to simple glycemic control. FIB-4, used as a marker for liver fibrosis which is often associated with hyperglycemia and hyperlipidemia and of the same potential mechanism as metabolic cardiac fibrosis was attractive in that age as detected in our low group model iteration, platelets, AST and ALT are its

formulaic components, however we did not find an association between FIB-4 and measures of diastolic dysfunction.

2 measures of diastolic function were used to assess the AGE-myocardial hypertrophy hypothesis.²³ Left atrial volume was seen as reflective of “the cumulative chronic effect of LV filling pressure over time”. The E/e’ ratio was also used as a doppler measure of diastolic function because it combines the ratio of a trans mitral flow measurement (a marker for the trans mitral pressure gradient) with a tissue doppler measurement (a marker of LV diastolic pressure) which is more sensitive for diastolic dysfunction.²⁴

Distinguishing glyco% as a compliance marker for progressive cardiac diastolic dysfunction beyond a non-specific vascular risk marker has been demonstrated.²⁵ This distinction is what sets diabetic cardiomyopathy apart from standard diabetic vascular risk factors and raises the specter of earlier hemodynamic primary preventative cardiac therapy even earlier than standard glycemic goals may dictate, especially in light of sglt2 inhibitor effects.

Conclusion--In patients with clinical cardiovascular risk characterized as stage A heart failure, glyco% can be used as a sensitive marker to identify those most at risk for disease progression based on diastolic hemodynamic parameters. Additionally, the glyco% can be used to identify those who may benefit from preventative cardiovascular treatment via the natriuretic effects of newer glycemic agents prior to a glycemic indication for therapy.

Tables and Figures

Table 1: Descriptive statistics continuous parameters evaluated in the study cohort

Variable	Mean	Std Dev	Range
Age _{yrs}	69.245	12.916	(31 - 94)
BMI _{kg/m²}	30.559	9.055	(14.8 - 55)
BSA _{m²}	1.941	0.334	(1.28 - 2.85)
Glyco%	6.850	1.879	(4.7 - 14)
BNP _{pg/ml}	2487.9	4733.9	(6 - 35000)
Fib4	2.427	2.773	(0.26 - 21.47)
LAVI _{ml/m²}	34.176	12.372	(11 - 69)
LADI _{cm/m²}	2.077	0.473	(1.2 - 4.1)
E _{m/sec}	1.005	0.346	(0.088 - 2.074)
Lat e' _{m/sec}	0.107	0.161	(0.035 - 1.23)
E/e'	13.936	6.041	(4 - 34)

Table 2: Descriptive statistics of categorical parameters evaluated in the study cohort

Variable	Frequency	Percent
Gender		
Female	58	56.86
Male	44	43.14
CADrwma		
No	76	74.51
Yes	26	25.49
Valve Disease		
No	95	93.14
Yes	7	6.86
HTN		
No	23	22.55
Yes	79	77.45

239

240

241

242

243 Figure 1: Risk ratio parameter estimates of Glyco% and Fib-4 models. Sex (M/F)
 244 and comorbidities (Yes/No) were defined as parametric responses while age, BMI,
 245 BNP, LAVI and E/e' were defined as spline smoothing components. Significantly
 246 associated effects ($P < 0.05$) are marked by an asterisk (*).

Figure 2: Spline smoothing component evaluation of deviance for linearly defined parameters in the generalized additive models. Curve-wise confidence band is at 95% confidence level. P values presented are for the analysis of deviance of each spline smoothing component where significant deviance is declared at $P < 0.05$.

Table 3: Low group vs high group parameter estimates. “Low group” being defined as having Glyco% 6.5 or less while the “high group” being defined as having Glyco% over 6.5. Groupings were evaluated independently for each Glyco% and Fib-4. Sex (M/F) and comorbidities (Yes/No) were defined as parametric responses while age, BMI, BNP, LAVI and E/e' were defined as spline smoothing components. Significantly associated effects ($P < 0.05$) are marked by an asterisk (*).

Parameter	Low Group Glyco% (6.5% or less)			High Group Glyco% (Over 6.5%)		
	Estimate	Standard Error	P	Estimate	Standard Error	P
Glyco%						
Gender: F	-0.019	0.123	0.8782	0.720	0.688	0.3074
CADrwma: No	0.003	0.125	0.9811	0.980	0.847	0.2600
Valve disease: No	0.264	0.183	0.1581	-0.595	1.582	0.7107
HTN: No	0.153	0.136	0.2667	-0.810	0.947	0.4023
Linear(Age)	0.009	0.005	0.0472*	-0.023	0.029	0.4366
Linear(BMI)	0.014	0.008	0.0865	-0.044	0.040	0.2781
Linear(BNP)	1.9E-05	9.7E-06	0.0621	1.1E-04	1.2E-04	0.3634
Linear(LAVI)	-0.004	0.005	0.4711	-0.015	0.028	0.5918
Linear(E/E')	0.008	0.012	0.4953	0.090	0.057	0.1264
Fib4						
Gender: F	0.790	0.915	0.3947	-0.547	0.598	0.3710
CADrwma: No	0.934	0.923	0.3196	-0.775	0.736	0.3039
Valve disease: No	0.973	1.354	0.4776	2.077	1.374	0.1456
HTN: No	0.801	1.005	0.4317	-1.596	0.823	0.0660
Linear(Age)	-0.020	0.033	0.5518	-0.015	0.025	0.5597
Linear(BMI)	0.051	0.057	0.3772	0.011	0.035	0.7615
Linear(BNP)	6.0E-05	7.2E-05	0.4089	5.8E-05	1.1E-04	0.5952
Linear(LAVI)	0.019	0.039	0.6280	-0.022	0.025	0.3854
Linear(E/E')	-0.066	0.088	0.4575	-0.014	0.049	0.7858

Bibliography

1. Fowler MJ. Microvascular and Macrovascular Complications of Diabetes. Clinical Diabetes. 2011;29(3). doi:10.2337/diaclin.29.3.116
2. The UK Prospective Diabetes Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352 (9131):837-853
3. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine. 1993;329(14). doi:10.1056/NEJM199309303291401
4. Beckman JA, Creager MA, Libby P. Diabetes and Atherosclerosis. JAMA. 2002;287(19). doi:10.1001/jama.287.19.2570

- 273 5. Fox CS. Trends in Cardiovascular Complications of Diabetes. JAMA.
274 2004;292(20). doi:10.1001/jama.292.20.2495
- 275 6. van Heerebeek L, Hamdani N, Handoko ML, et al. Diastolic Stiffness of the
276 Failing Diabetic Heart. Circulation. 2008;117(1).
277 doi:10.1161/CIRCULATIONAHA.107.728550
- 278 7. Levelt E, Gulsin G, Neubauer S, McCann GP. MECHANISMS IN
279 ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential
280 metabolic interventions state of the art review. European Journal of
281 Endocrinology. 2018;178(4). doi:10.1530/EJE-17-0724
- 282 8. Singh VP, Bali A, Singh N, Jaggi AS. Advanced Glycation End Products and
283 Diabetic Complications. The Korean Journal of Physiology & Pharmacology.
284 2014;18(1). doi:10.4196/kjpp.2014.18.1.1
- 285 9. Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in
286 diabetic cardiomyopathy. Nature Reviews Endocrinology. 2016;12(3).
287 doi:10.1038/nrendo.2015.216
- 288 10. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update
289 for the Diagnosis and Management of Chronic Heart Failure in the Adult—
290 Summary Article. Circulation. 2005;112(12).
291 doi:10.1161/CIRCULATIONAHA.105.167587
- 292 11. Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and Prognostic
293 Significance of Heart Failure Stages. Circulation. 2007;115(12).
294 doi:10.1161/CIRCULATIONAHA.106.666818
- 295 12. Mahaffey KW, Jardine MJ, Bompont S, et al. Canagliflozin and
296 Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic
297 Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
298 Circulation. 2019;140(9). doi:10.1161/CIRCULATIONAHA.119.042007
- 299 13. Lam CSP, Chandramouli C, Ahooja V, Verma S. SGLT-2 Inhibitors in Heart
300 Failure: Current Management, Unmet Needs, and Therapeutic Prospects. Journal
301 of the American Heart Association. 2019;8(20). doi:10.1161/JAHA.119.013389

14. From AM, Scott CG, Chen HH. The Development of Heart Failure in Patients With Diabetes Mellitus and Pre-Clinical Diastolic Dysfunction. *Journal of the American College of Cardiology*. 2010;55(4). doi:10.1016/j.jacc.2009.12.003
15. Older Adults: Standards of Medical Care in Diabetes—2019. *Diabetes Care*. 2019;42(Supplement 1). doi:10.2337/dc19-S012
16. Lang RM, Bierig M, Devereux RB, et al. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. *Journal of the American Society of Echocardiography*. 2005;18(12). doi:10.1016/j.echo.2005.10.005
17. Verbraecken J, van de Heyning P, de Backer W, van Gaal L. Body surface area in normal-weight, overweight, and obese adults. A comparison study. *Metabolism*. 2006;55(4). doi:10.1016/j.metabol.2005.11.004
18. Stefano GT, Zhao H, Schluchter M, Hoit BD. Assessment of Echocardiographic Left Atrial Size: Accuracy of M-Mode and Two-Dimensional Methods and Prediction of Diastolic Dysfunction. *Echocardiography*. 2012;29(4). doi:10.1111/j.1540-8175.2011.01643.x
19. Singh VP, Bali A, Singh N, Jaggi AS. Advanced Glycation End Products and Diabetic Complications. *The Korean Journal of Physiology & Pharmacology*. 2014;18(1). doi:10.4196/kjpp.2014.18.1.1
20. Dozio E, Vianello E, Bandera F, et al. Soluble Receptor for Advanced Glycation End Products: A Protective Molecule against Intramyocardial Lipid Accumulation in Obese Zucker Rats? *Mediators of Inflammation*. 2019;2019. doi:10.1155/2019/2712376
21. Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. *Nature*

Reviews Gastroenterology & Hepatology. 2018;15(7). doi:10.1038/s41575-018-0010-0

22. Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and Prognostic Significance of Heart Failure Stages. Circulation. 2007;115(12). doi:10.1161/CIRCULATIONAHA.106.666818

23. Andersen OS, Smiseth OA, Dokainish H, et al. Estimating Left Ventricular Filling Pressure by Echocardiography. Journal of the American College of Cardiology. 2017;69(15). doi:10.1016/j.jacc.2017.01.058

24. Mitter SS, Shah SJ, Thomas JD. A Test in Context. Journal of the American College of Cardiology. 2017;69(11). doi:10.1016/j.jacc.2016.12.037

25. van Heerebeek L, Hamdani N, Handoko ML, et al. Diastolic Stiffness of the Failing Diabetic Heart. Circulation. 2008;117(1). doi:10.1161/CIRCULATIONAHA.107.728550